VladonixВладоникс
An oral peptide mixture extracted from calf or pig thymus, studied in Russian immune-function reports.
What the studies found
Observational study · 2013
Oral peptide combinations in Agent Orange-exposed veterans with immune deficiency
Study of multiple preparations
- IgG
- 1,202.27 → 1,445.20 mg/dLBefore and after the combination.p<0.01
- CD4 cells
- 501.96 → 569.33 cells/µLp<0.01
- IgM
- 126.56 → 132.46 mg/dLp<0.01
In 150 veterans, mean IgG rose from 1,202.27 to 1,445.20 mg/dL and CD4 cells from 501.96 to 569.33 cells/µL (both p<0.01). CD19 and the CD4/CD8 ratio did not change significantly.
More reported outcomes
- CD3 and CD8 cells
- 963.01 → 1,088.78 and 389.72 → 438.10 cells/µLp<0.01 and p<0.05, respectively
- IgA, CD19 and CD4/CD8 ratio
- No statistically significant changep>0.05
- Author-defined overall outcome
- 105/150 good, 45/150 fairNo untreated group for this rating.
Study notes · methods, sources and limitations
Participants or model 150 veterans with immune deficiency in the Joint Vietnam–Russia Program 33. The same 150 are shown before and after treatment.
Design The researchers compared immunoglobulins and lymphocyte markers before and after the 20-day regimen. Tables show paired assessment denominators of 150. The reference laboratory column is a population benchmark.
Important limitations
- This was a before-and-after study of three products with no concurrent untreated group. Individual product effects and effects on infection risk remain uncertain. Program 33 reports 300 participants across two clinical series. The relationship between the two participant lists remains unverified.
Journal of Tropical Science and Technology. 2013;(2):78–84. · Publication record
Comparison in people · 2022
Vladonix with recombinant IL-2 and interferon in COVID-19 outpatients
- Moderate disease · duration
- 14 ± 1.9 vs 16 ± 2.2 daysAdjunct combination versus standard care, Table 1. The text gives 14.2 ± 2.2 vs 16.2 ± 2.4.
- Moderate disease · post-COVID symptoms
- 3/12 vs 7/12Adjunct combination versus standard care. Recovery among these patients averaged 32.2 vs 36.2 days.
- Worsening and reported adverse effects
- No cases reportedNo group-level adverse-event table or systematic assessment method is provided.
In the 24-person moderate-disease comparison, Table 1 reports mean illness duration of 14 vs 16 days and post-COVID symptoms in 3 of 12 vs 7 of 12 patients with combination treatment versus standard care.
Study notes · methods, sources and limitations
Participants or model 48 PCR-confirmed outpatients aged 18–50 in Almaty and Semey, Kazakhstan. Mild and moderate disease each had 12 adjunct-treatment and 12 standard-care patients.
Design Each severity stratum had 12 patients per arm. Only the acute moderate combination included Vladonix. All patients received standard care.
Important limitations
- Group assignment and masking are unclear. The combination prevents attribution to Vladonix alone. The illness-duration means differ slightly between Table 1 and the narrative. Post-COVID criteria and systematic adverse-event collection are not described.
- The four small groups tested severity-specific combinations. They do not establish a separate Vladonix effect.
Terapevt. 2022(4):34–39 · Original journal article
Comparison in people · 2006
Vladonix: clinical report on a tissue-derived preparation
- CD4-positive cells
- 34.6% vs 30.8%Vladonix plus usual care versus usual care. Shared baseline 28.5%.Vladonix value marked p < 0.05 versus baseline.
- CD3-positive cells
- 55.7% vs 51.9%Shared baseline 46.5%.Vladonix value marked p < 0.05 versus baseline.
- CD4/CD8 ratio
- 1.4 vs 1.2Shared baseline 1.1.Vladonix value marked p < 0.05 versus baseline.
In the 76-person institute report, CD4-positive cells were 34.6% after adjunctive oral Vladonix and 30.8% after usual care, compared with a shared 28.5% baseline column.
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
More reported outcomes
- IgM, IgG, IgA and CD8-positive cells
- No significant change markedTable 2 significance markers do not apply to these rows.
Study notes · methods, sources and limitations
Participants or model 76 patients: 42 adjunctive Vladonix; 34 controls. Prior low-dose radiation exposure or radiation/chemotherapy.
Design 42 received adjunctive Vladonix and 34 conventional treatment alone. Peripheral-blood immunophenotyping used immunofluorescence. Immunoglobulins were measured by radial immunodiffusion.
Important limitations
- Sex counts differ between prose and table. Immune biomarkers do not establish protection from radiation, fewer infections or improved cancer outcomes. Commercially reproduced institute report; independent peer review and independent replication are not established by this document. Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
- The report provides a shared baseline column and no clear between-arm test. Its biomarker results do not establish fewer infections or better cancer outcomes.
Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date · Institute report — commercial reproduction
About Vladonix
Identity / background source ↗
Research background
Vladonix is a thymus-derived peptide preparation. Studies measured blood immune markers following radiation exposure and assessed symptoms in a multi-drug COVID-19 comparison.
Performance research in context
- Compound class
- Tissue-derived peptide preparation
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
A 76-person report and a 48-person journal comparison. Acute Vladonix exposure was limited to the combination in the moderate COVID-19 subgroup.
Study methods
Small comparative institute report; allocation, blinding and outcome interpretation require caution
Independent replication
Independent replication not established in this collection
Source access
Original journal reports and reproduced institute data.
Safety evidence
Short-term reports do not establish long-term safety or equivalence to current products
Open a topic for the evidence assessment.
Findings by study
Tissue-preparation reports: comparisons, source limits and remaining gaps ↗
Observational study · 2013
Oral peptide combinations in Agent Orange-exposed veterans with immune deficiency
In 150 veterans, mean IgG rose from 1,202.27 to 1,445.20 mg/dL and CD4 cells from 501.96 to 569.33 cells/µL (both p<0.01). CD19 and the CD4/CD8 ratio did not change significantly.
Study notes and original source
Oral peptide combinations in Agent Orange-exposed veterans with immune deficiency
Vladoniks, Vezugen and Kristagen as named in the paper. Branded oral preparations.
Hoàng Văn Huấn, Phạm Khắc Linh, Nguyễn Như Nghĩa, and colleagues · Journal of Tropical Science and Technology. 2013;(2):78–84.
In 150 veterans, mean IgG rose from 1,202.27 to 1,445.20 mg/dL and CD4 cells from 501.96 to 569.33 cells/µL (both p<0.01). CD19 and the CD4/CD8 ratio did not change significantly.
Results and tables
Reported findings and study design
The researchers compared immunoglobulins and lymphocyte markers before and after the 20-day regimen. Tables show paired assessment denominators of 150. The reference laboratory column is a population benchmark.
Population or model 150 veterans with immune deficiency in the Joint Vietnam–Russia Program 33. The same 150 are shown before and after treatment.
Dose, route and schedule
Vladoniks, Vezugen and Kristagen were taken orally for 20 days. The paper lists 0.2 g of each preparation. It does not give purified peptide content or capsule frequency.
Protocol source ↗ · Original journal PDF, methods and Tables 1–6. Parent program report and Ministry of Defence project citation checked.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| IgG | 1,202.27 → 1,445.20 mg/dL | Before and after the combination. · p<0.01 |
| CD4 cells | 501.96 → 569.33 cells/µL | p<0.01 |
| IgM | 126.56 → 132.46 mg/dL | p<0.01 |
| CD3 and CD8 cells | 963.01 → 1,088.78 and 389.72 → 438.10 cells/µL | p<0.01 and p<0.05, respectively |
| IgA, CD19 and CD4/CD8 ratio | No statistically significant change | p>0.05 |
| Author-defined overall outcome | 105/150 good, 45/150 fair | No untreated group for this rating. |
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 150 veterans with immune deficiency in the Joint Vietnam–Russia Program 33. The same 150 are shown before and after treatment.
- Source reviewed
- Original journal PDF, methods and Tables 1–6. Parent program report and Ministry of Defence project citation checked.
Study limitations
- This was a before-and-after study of three products with no concurrent untreated group. Individual product effects and effects on infection risk remain uncertain.
- Program 33 reports 300 participants across two clinical series. The relationship between the two participant lists remains unverified.
Reviewed 2026-11-14.
Comparison in people · 2022
Vladonix with recombinant IL-2 and interferon in COVID-19 outpatients
In the 24-person moderate-disease comparison, Table 1 reports mean illness duration of 14 vs 16 days and post-COVID symptoms in 3 of 12 vs 7 of 12 patients with combination treatment versus standard care.
Moderate disease · duration · 14 ± 1.9 vs 16 ± 2.2 days · Adjunct combination versus standard care, Table 1. The text gives 14.2 ± 2.2 vs 16.2 ± 2.4.
Study notes and original source
Vladonix with recombinant IL-2 and interferon in COVID-19 outpatients
Oral Vladonix A-6 thymus peptide complex, given with injectable recombinant IL-2 and intranasal interferon in the acute moderate branch. · Original journal article
N. Serikov, A. Zinatollayeva, Z. Karimova, N. K. Kudaibergenova, G. Zh. Abdrakhmanova, D. B. Kozubaeva, F. F. Yagofarov · Terapevt. 2022(4):34–39
In the 24-person moderate-disease comparison, Table 1 reports mean illness duration of 14 vs 16 days and post-COVID symptoms in 3 of 12 vs 7 of 12 patients with combination treatment versus standard care.
Results and tables
Reported findings and study design
Each severity stratum had 12 patients per arm. Only the acute moderate combination included Vladonix. All patients received standard care.
Population or model 48 PCR-confirmed outpatients aged 18–50 in Almaty and Semey, Kazakhstan. Mild and moderate disease each had 12 adjunct-treatment and 12 standard-care patients.
Dose, route and schedule
Moderate disease: Vladonix one capsule twice daily during illness with intranasal interferon alfa-2b and Roncoleukin (500,000 IU for 6–8 days). Acute mild disease received interferon and Roncoleukin without Vladonix. The post-COVID sections describe Vladonix for 10 or 30 days alongside Roncoleukin. Capsule peptide mass is unspecified.
Protocol source ↗ · Original journal PDF, methods and Table 1
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Moderate disease · duration | 14 ± 1.9 vs 16 ± 2.2 days | Adjunct combination versus standard care, Table 1. The text gives 14.2 ± 2.2 vs 16.2 ± 2.4. |
| Moderate disease · post-COVID symptoms | 3/12 vs 7/12 | Adjunct combination versus standard care. Recovery among these patients averaged 32.2 vs 36.2 days. |
| Worsening and reported adverse effects | No cases reported | No group-level adverse-event table or systematic assessment method is provided. |
Table 1 · illness duration and post-COVID cases
| Group | n | Illness (days) | Post-COVID cases | Recovery (days) |
|---|---|---|---|---|
| Mild · interferon + IL-2 | 12 | 8 ± 1.2 | 0 | — |
| Mild · usual care | 12 | 10 ± 1.8 | 1 | 28 |
| Moderate · Vladonix + interferon + IL-2 | 12 | 14 ± 1.9 | 3 | 32.2 |
| Moderate · usual care | 12 | 16 ± 2.2 | 7 | 36.2 |
Table 1 means are used for acute illness. For moderate post-COVID recovery the prose gives ±4.5 and ±4.1 days, respectively. The corresponding table uncertainty fields are malformed.
The four small groups tested severity-specific combinations. They do not establish a separate Vladonix effect.
Source for these results ↗ · Reviewed 2026-11-13
- Population / setting
- 48 PCR-confirmed outpatients aged 18–50 in Almaty and Semey, Kazakhstan. Mild and moderate disease each had 12 adjunct-treatment and 12 standard-care patients.
- Source reviewed
- Original journal PDF, methods and Table 1
Study limitations
- Group assignment and masking are unclear. The combination prevents attribution to Vladonix alone.
- The illness-duration means differ slightly between Table 1 and the narrative. Post-COVID criteria and systematic adverse-event collection are not described.
Reviewed 2026-11-13.
Lab research · 2016
Vladonix, Endoluten and other peptides in cultured human blood cells
In cultured blood cells, Vladonix raised lysate IL-18 to 66.48 vs 39.06 pg/mL and lowered IL-1RA to 3,765 vs 5,228 pg/mL relative to saline.
Study notes and original source
Vladonix, Endoluten and other peptides in cultured human blood cells
Six separately assayed peptide preparations supplied by the Khavinson laboratory. · Original journal article
M. V. Maksimenya, E. V. Fefelova, A. S. Bykova · Actual Problems of Humanities and Natural Sciences. 2016;12-3:97–100
Vladonix increased cell-lysate IL-18 to a median of 66.48 vs 39.06 pg/mL with saline and lowered IL-1RA to 3,765 vs 5,228 pg/mL. The study compared six preparations in cell culture.
Results and tables
Reported findings and study design
Saline-controlled cultures from 15 donors, 0.4 µg/mL for 24 hours. Lysate and supernatant were analyzed separately.
Population or model Peripheral-blood mononuclear cells from 15 volunteers. Mean donor age 41 ± 19 years, 73% men.
Dose, route and schedule
Cells were exposed to 0.4 µg/mL of each preparation or volume-matched saline for 24 hours at 37 °C. Cytokines were measured by ELISA in cell lysates and culture supernatant.
Protocol source ↗ · Original journal PDF, methods, Table 1 and culture-supernatant results
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Vladonix · lysate IL-18 | 66.48 vs 39.06 pg/mL | Median with Vladonix versus saline. · p < 0.001 |
| Vladonix · lysate IL-1RA | 3,765 vs 5,228 pg/mL | Median with Vladonix versus saline. · p = 0.006 |
| Endoluten · lysate IL-18 and IL-4 | 65.11 vs 39.06 and 28.40 vs 12.24 pg/mL | Endoluten versus saline. · p = 0.02 and p < 0.001, respectively. |
| Crystagen and Cortexin · lysate IL-18 | 75.10 and 60.02 vs 39.06 pg/mL | Each preparation versus saline. Crystagen’s printed interval is inconsistent. · p = 0.004 and p = 0.04, respectively. |
| Vilon · lysate TNF-α and IL-1RA | 904.04 vs 598.05 and 4,056 vs 5,228 pg/mL | Vilon versus saline. · p = 0.045 and p = 0.02, respectively. |
| Epitalon · lysate IL-1RA | 4,346 vs 5,228 pg/mL | Epitalon versus saline. · p = 0.047 |
| Culture supernatant | Endoluten IL-18 +33.46% and Vilon TNF-α +41.13% | These were the only significant supernatant changes reported. Neither of the two Vladonix lysate findings was reported as significant in supernatant. · p = 0.02 and p = 0.035, respectively. |
Table 1 · cell-lysate cytokines
| Preparation | IL-18 (pg/mL) | TNF-α (pg/mL) | IL-4 (pg/mL) | IL-1RA (pg/mL) |
|---|---|---|---|---|
| Saline | 39.06 | 598.05 | 12.24 | 5,228 |
| Vladonix | 66.48* | 706.54 | 17.62 | 3,765* |
| Endoluten | 65.11* | 429.02 | 28.40* | 4,860 |
| Crystagen | 75.10* | 505.26 | 20.47 | 4,772 |
| Vilon | 34.74 | 904.04* | 9.96 | 4,056* |
| Epitalon | 30.62 | 548.00 | 9.50 | 4,346* |
| Cortexin | 60.02* | 693.00 | 15.04 | 4,921 |
Printed medians. Asterisks mark comparisons with saline at p < 0.05. The Crystagen IL-18 interquartile interval is printed as 66.46–70.62, which excludes the printed median.
The experiment measures cytokine concentrations after direct contact with cells. The clinical meaning and relevance to swallowing a capsule remain unknown.
Source for these results ↗ · Reviewed 2026-11-13
- Population / setting
- Peripheral-blood mononuclear cells from 15 volunteers. Mean donor age 41 ± 19 years, 73% men.
- Source reviewed
- Original journal PDF, methods, Table 1 and culture-supernatant results
Study limitations
- The volunteers donated blood and did not receive treatment. Culture concentrations cannot establish oral exposure or clinical effects.
- The Crystagen IL-18 median lies outside its printed interquartile interval. Some narrative percentages differ from ratios calculated from tabulated medians.
Reviewed 2026-11-13.
Comparison in people · 2006
Vladonix: clinical report on a tissue-derived preparation
In the 76-person institute report, CD4-positive cells were 34.6% after adjunctive oral Vladonix and 30.8% after usual care, compared with a shared 28.5% baseline column.
Study notes and original source
Vladonix: clinical report on a tissue-derived preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date
In the 76-person institute report, CD4-positive cells were 34.6% after adjunctive oral Vladonix and 30.8% after usual care, compared with a shared 28.5% baseline column.
Results and tables
Reported findings and study design
42 received adjunctive Vladonix and 34 conventional treatment alone. Peripheral-blood immunophenotyping used immunofluorescence. Immunoglobulins were measured by radial immunodiffusion.
Population or model 76 patients: 42 adjunctive Vladonix; 34 controls. Prior low-dose radiation exposure or radiation/chemotherapy.
Dose, route and schedule
One to three oral capsules, two to three times daily before meals for 15–20 days. The report lists 10 mg of thymus extract per capsule. Both arms received conventional care.
Protocol source ↗ · Russian institute-report reproductions, methods and Table 2
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| CD4-positive cells | 34.6% vs 30.8% | Vladonix plus usual care versus usual care. Shared baseline 28.5%. · Vladonix value marked p < 0.05 versus baseline. |
| CD3-positive cells | 55.7% vs 51.9% | Shared baseline 46.5%. · Vladonix value marked p < 0.05 versus baseline. |
| CD4/CD8 ratio | 1.4 vs 1.2 | Shared baseline 1.1. · Vladonix value marked p < 0.05 versus baseline. |
| IgM, IgG, IgA and CD8-positive cells | No significant change marked | Table 2 significance markers do not apply to these rows. |
The report provides a shared baseline column and no clear between-arm test. Its biomarker results do not establish fewer infections or better cancer outcomes.
Source for these results ↗ · Reviewed 2026-11-13
- Population / setting
- 76 patients: 42 adjunctive Vladonix; 34 controls. Prior low-dose radiation exposure or radiation/chemotherapy.
- Source reviewed
- Russian institute-report reproductions, methods and Table 2
Study limitations
- Sex counts differ between prose and table. Immune biomarkers do not establish protection from radiation, fewer infections or improved cancer outcomes.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Reviewed 2026-11-13.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗